OR WAIT null SECS
Pharmaceutical Technology Europe® spoke with Gautam Shetty from Congruence Medical Solutions, a US drug delivery device company, at the inaugural Start-Up Market on the show floor at CPHI Barcelona 2023.
Biologic drug products are becoming ever more present in the development pipeline, with healthy growth anticipated in the sector over the next few years (1). However, delivery of these complex molecules is not always straight-forward; in particular, when trying to deliver high doses of viscous biological drug products, common delivery devices that patients rely on to be able to self-administer their therapies are not always suitable for use.
The issue of delivering high dose, large volume, highly viscous biologics is what Congruence Medical Solutions, a start-up company incorporated in 2015 and based in the United States, specializes in. To learn more about the company and how it is tackling the issue of delivering viscous biologics in high doses, Pharmaceutical Technology Europe® spoke with CEO and founder, Gautam Shetty, at CPHI Barcelona 2023.
"We are a US-based drug delivery device company that’s engaged in the design, development, and supply of innovative drug delivery devices," revealed Shetty. "We work on addressing the unmet needs, emerging needs, and really hard to solve problems in injectable drug delivery."
The company focuses on three key areas: “microliter dosing; injection of high-dose biologics or viscous formulations; and minimizing drug waste at the point of injection,” Shetty added.
Shetty pointed out that some biologics can have a viscosity greater than 1000 centipoises, but despite this, he stated that most biologics can be addressed so long as it is possible to inject at a viscosity of 100 centipoises or lower. “We have worked on applications, maybe, as high as 1500 centipoises,” he specified.
In terms of their approach to drug delivery problems, Shetty pointed out that Congruence Medical Solutions are not the same as traditional drug delivery suppliers. “We really bring something to the table that traditional suppliers of drug delivery devices don’t,” he said. “We often joke that we work on things that other won’t or cannot do.”
Grand View Research. Biologics Market Size, Share, and Trends Analysis Report by Source (Microbial, Mammalian), by Product (mAbs, Recombinant Proteins, Antisense, and RNAi), by Disease Category, by Manufacturing, by Region, and Segment Forecasts, 2023–2030. Market Report (May 2023).
Congruence Medical Solutions was featured at the inaugural Start-Up Market on the show floor at CPHI Barcelona 2023. CPHI Barcelona ran from Oct. 24–26, 2023.